Intra-Cellular Therapies Inc (ITCI)
66.53
-0.31
(-0.46%)
USD |
NASDAQ |
May 16, 16:00
66.56
+0.03
(+0.05%)
After-Hours: 20:00
Intra-Cellular Therapies Cash from Investing (Quarterly): 16.18M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 16.18M |
| December 31, 2023 | 47.42M |
| September 30, 2023 | -20.17M |
| June 30, 2023 | 94.75M |
| March 31, 2023 | -16.46M |
| December 31, 2022 | 50.26M |
| September 30, 2022 | 106.17M |
| June 30, 2022 | 37.23M |
| March 31, 2022 | -322.04M |
| December 31, 2021 | 51.51M |
| September 30, 2021 | 63.77M |
| June 30, 2021 | 48.79M |
| March 31, 2021 | 116.27M |
| December 31, 2020 | -176.34M |
| September 30, 2020 | -143.22M |
| June 30, 2020 | -7.758M |
| March 31, 2020 | -152.98M |
| December 31, 2019 | 37.74M |
| September 30, 2019 | 40.24M |
| June 30, 2019 | 54.72M |
| March 31, 2019 | 44.74M |
| Date | Value |
|---|---|
| December 31, 2018 | 14.15M |
| September 30, 2018 | 28.26M |
| June 30, 2018 | 28.95M |
| March 31, 2018 | 63.28M |
| December 31, 2017 | -151.88M |
| September 30, 2017 | 37.16M |
| June 30, 2017 | 30.87M |
| March 31, 2017 | -8.870M |
| December 31, 2016 | 1.677M |
| September 30, 2016 | 52.97M |
| June 30, 2016 | 28.05M |
| March 31, 2016 | 9.568M |
| December 31, 2015 | -250.94M |
| September 30, 2015 | -45.58M |
| June 30, 2015 | 1.447M |
| March 31, 2015 | -66.70M |
| December 31, 2014 | -1.448M |
| September 30, 2014 | -17.83M |
| June 30, 2014 | -47.45M |
| March 31, 2014 | -0.0031M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-322.04M
Minimum
Mar 2022
116.27M
Maximum
Mar 2021
-3.695M
Average
38.99M
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -464.00M |
| Insmed Inc | 295.32M |
| Madrigal Pharmaceuticals Inc | 98.05M |
| Vertex Pharmaceuticals Inc | -2.136B |
| Fate Therapeutics Inc | 17.31M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -34.12M |
| Cash from Financing (Quarterly) | 9.989M |
| Free Cash Flow | -98.25M |
| Free Cash Flow Per Share (Quarterly) | -0.3522 |
| Free Cash Flow to Equity (Quarterly) | -34.12M |
| Free Cash Flow to Firm (Quarterly) | -34.12M |
| Free Cash Flow Yield | -1.53% |